206 related articles for article (PubMed ID: 9674734)
21. Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin on hemostatic properties of endothelium.
Pérez-Ruiz A; Montes R; Carrasco P; Rocha E
Clin Appl Thromb Hemost; 2002 Jan; 8(1):65-71. PubMed ID: 11991242
[TBL] [Abstract][Full Text] [Related]
22. Heparin/low molecular weight heparin and tissue factor pathway inhibitor.
Abildgaard U
Haemostasis; 1993 Mar; 23 Suppl 1():103-6. PubMed ID: 8388347
[TBL] [Abstract][Full Text] [Related]
23. Reduction of factor FVIIa activity during heparin therapy. Evidence for assay interactions with tissue factor pathway inhibitor and antithrombin.
Hansen JB; Svensson B; Sandset PM; Thijssen F
Thromb Res; 2000 Dec; 100(5):389-96. PubMed ID: 11150580
[TBL] [Abstract][Full Text] [Related]
24. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro.
Hansen JB; Svensson B; Olsen R; Ezban M; Osterud B; Paulssen RH
Thromb Haemost; 2000 Jun; 83(6):937-43. PubMed ID: 10896252
[TBL] [Abstract][Full Text] [Related]
25. Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.
Wood JP; Baumann Kreuziger LM; Desai UR; Mast AE
Br J Haematol; 2016 Oct; 175(1):123-32. PubMed ID: 27301751
[TBL] [Abstract][Full Text] [Related]
26. Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin.
Harenberg J; Malsch R; Angelescu M; Lange C; Michaelis HC; Wolf H; Heene DL
Blood Coagul Fibrinolysis; 1996 Jun; 7(4):477-83. PubMed ID: 8840001
[TBL] [Abstract][Full Text] [Related]
27. A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans.
Kaiser B; Glusa E; Hoppensteadt DA; Breddin HK; Amiral J; Fareed J
Blood Coagul Fibrinolysis; 1998 Sep; 9(6):517-23. PubMed ID: 9819002
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of coagulation and platelet adhesion to extracellular matrix by unfractionated heparin and a low molecular weight heparin.
Krupinski K; Basic-Micic M; Lindhoff E; Breddin HK
Blut; 1990 Nov; 61(5):289-94. PubMed ID: 2176900
[TBL] [Abstract][Full Text] [Related]
29. Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma.
Alban S
Semin Thromb Hemost; 2001 Oct; 27(5):503-11. PubMed ID: 11668420
[TBL] [Abstract][Full Text] [Related]
30. A low-molecular-weight heparin (Kabi 2165, 'Fragmin') in repeated use for haemodialysis: prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin.
Anastassiades E; Ireland H; Flynn A; Lane DA; Curtis JR
Nephrol Dial Transplant; 1990; 5(2):135-40. PubMed ID: 2162506
[TBL] [Abstract][Full Text] [Related]
31. Low-molecular-weight heparins in thrombosis and cancer: emerging links.
Mousa SA
Cardiovasc Drug Rev; 2004; 22(2):121-34. PubMed ID: 15179449
[TBL] [Abstract][Full Text] [Related]
32. Preclinical studies on a low molecular weight heparin.
Fareed J; Jeske W; Eschenfelder V; Iqbal O; Hoppensteadt D; Ahsan A
Thromb Res; 1996; 81(2 Suppl):S1-27. PubMed ID: 8822124
[TBL] [Abstract][Full Text] [Related]
33. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations.
Ostergaard P; Nordfang O; Petersen LC; Valentin S; Kristensen H
Haemostasis; 1993 Mar; 23 Suppl 1():107-11. PubMed ID: 8388348
[TBL] [Abstract][Full Text] [Related]
34. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves.
Maegdefessel L; Linde T; Krapiec F; Hamilton K; Steinseifer U; van Ryn J; Raaz U; Buerke M; Werdan K; Schlitt A
Thromb Res; 2010 Sep; 126(3):e196-200. PubMed ID: 20659761
[TBL] [Abstract][Full Text] [Related]
35. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor.
Bara L; Bloch MF; Zitoun D; Samama M; Collignon F; Frydman A; Uzan A; Bouthier J
Thromb Res; 1993 Mar; 69(5):443-52. PubMed ID: 8388583
[TBL] [Abstract][Full Text] [Related]
36. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro.
Westmuckett AD; Kakkar VV; Hamuro T; Lupu F; Lupu C
Thromb Haemost; 2001 Dec; 86(6):1547-54. PubMed ID: 11776326
[TBL] [Abstract][Full Text] [Related]
37. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
[TBL] [Abstract][Full Text] [Related]
38. Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells.
Martinez-Sales V; Vila V; Réganon E; Oms JG; Aznar J
Haematologica; 2003 Jun; 88(6):694-9. PubMed ID: 12801846
[TBL] [Abstract][Full Text] [Related]
39. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
[TBL] [Abstract][Full Text] [Related]
40. Signs of thrombin generation in pediatric cardiac catheterization with unfractionated heparin bolus or subcutaneous low molecular weight heparin for antithrombotic cover.
Roschitz B; Beitzke A; Gamillscheg A; Sudi K; Koestenberger M; Leschnik B; Muntean W
Thromb Res; 2003; 111(6):335-41. PubMed ID: 14698650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
